Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage II-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial.

作者
Run‐Cong Nie,YingBo Chen,Jin Wan,Xiao-wei Sun,Wei-qin Hong,H. B. Wei,Jun-Sheng Peng,YingBo Chen,Zhiwei Zhou,Yuan-fang Li
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (2_suppl): 289-289
标识
DOI:10.1200/jco.2026.44.2_suppl.289
摘要

289 Background: In Asia, adjuvant S-1 monotherapy following D2 gastrectomy represents a standard treatment for patients with pathological stage II/III gastric or gastro-oesophageal junction (GEJ) carcinoma. We aimed to assess the efficacy and safety of adjuvant oxaliplatin plus S-1 versus S-1 administered in this setting. Methods: The CAPITAL trial was a multicentre, randomised, open-label, phase 3 study conducted at 13 hospitals in China. Eligible patients were aged 18 years or older with histologically confirmed pathological stage II-III gastric or GEJ adenocarcinoma after gastrectomy with D2 lymph node dissection, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Patients were randomly assigned (1:1) to receive SOX regimen (6 cycles of S-1 40-60 mg orally twice daily for 2 weeks in each 3-week cycle and oxaliplatin 100 mg/m 2 administered intravenously once every 3 weeks, followed by 10 additional cycles of S-1), or S-1 regimen (16 cycles of S-1 at a dose of 40-60 mg twice per day for 2 weeks, followed by a rest of 1 week). The primary endpoint was overall survival in the intention-to-treat population. Safety analysis were done in patients who received at least one dose of the trial drug. This study is registered with ClinicalTrials.gov, NCT01795027. Results: Between Oct 28, 2011 and Nov 3, 2017, 724 patients were randomly assigned to receive either adjuvant SOX (n=362) or adjuvant S-1 (n=362). By the clinical cutoff date of Nov 3, 2022, the median follow-up time was 74.0 months (IQR 35.5-89.3). The 5-year overall survival were 70.9% (95% CI 66.0-76.1) in the SOX group and 62.9% (57.8-68.5) in the S-1 group. The HR for death in the SOX group, as compared with the S-1 group, was 0.74 (0.58-0.95; p=0.018). The 3 and 5-year disease-free survival were 71.2% (66.5-76.3) and 66.2% (61.2-71.6) in the SOX group, as compared with 65.1% (60.2-70.5) and 55.6% (50.4-61.3) in the S-1 group. The HR of disease-free survival for the SOX group versus the S-1 group was 0.76 (0.61-0.96; p=0.021). Treatment-related adverse events of any grade occurred in 295 (85%) of 349 patients in the SOX group and 260 (75%) of 347 patients in the S-1 group. The most common grade 3-4 adverse events was neutropenia (44 (13%) of 349 patients in the SOX group and 23 (7%) of 347 patients in the S-1 group). No treatment-related deaths were recorded. Conclusions: The addition of oxaliplatin to S-1 chemotherapy significantly improved both overall survival and disease-free survival in patients with stage II-III gastric or GEJ adenocarcinoma. SOX regimen should be considered as a standard adjuvant treatment option for this patient population following D2 gastrectomy. Clinical trial information: NCT01795027 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LCD完成签到,获得积分10
1秒前
Vanli完成签到,获得积分10
1秒前
朴实紫菜完成签到 ,获得积分10
1秒前
奋青发布了新的文献求助10
1秒前
吉不二完成签到,获得积分10
1秒前
小月月发布了新的文献求助10
2秒前
Zz完成签到,获得积分10
2秒前
平淡的凌寒完成签到,获得积分10
2秒前
宋江他大表哥完成签到,获得积分10
2秒前
天天向上的应助被pcs采纳,获得10
2秒前
Wang完成签到,获得积分10
2秒前
木木完成签到,获得积分10
2秒前
孤高曼巴完成签到,获得积分10
2秒前
优雅的项链完成签到,获得积分10
3秒前
lili完成签到,获得积分10
3秒前
xiaoyaczl完成签到,获得积分10
4秒前
害羞菲鹰完成签到,获得积分10
4秒前
乌兰巴托没有海完成签到,获得积分10
5秒前
Vivian完成签到,获得积分10
5秒前
5秒前
小亦雪发布了新的文献求助10
5秒前
浅唱完成签到,获得积分10
5秒前
小板deng完成签到,获得积分10
5秒前
橙橙完成签到,获得积分10
6秒前
于归故城完成签到,获得积分10
6秒前
zbs完成签到,获得积分10
6秒前
songshu完成签到,获得积分10
6秒前
丫丫完成签到,获得积分10
6秒前
。。完成签到,获得积分10
7秒前
威武的友菱完成签到,获得积分10
7秒前
宇宙无敌暴龙战士完成签到 ,获得积分10
8秒前
8秒前
sjdd完成签到 ,获得积分10
8秒前
乐乐的应助被科研通管家采纳,获得10
8秒前
飞飞的应助被科研通管家采纳,获得30
8秒前
汉堡包的应助被科研通管家采纳,获得10
8秒前
lucky完成签到,获得积分10
9秒前
无花果的应助被科研通管家采纳,获得30
9秒前
文文的应助被科研通管家采纳,获得10
9秒前
su完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039